Image 1. Photograph of patient with minimally evident presentation of invasive fungal infection and old fibrotic scar (white arrow).
Image 2.
Right-sided mass with extension into ethmoid and maxillary sinuses (red circle).
craniectomy. Nasal turbinates were normal appearing. Neurologic examination was normal.
Complete blood count and electrolytes were within normal limits. Computed tomography of the face showed ethmoid and maxillary sinus bone destructions with extension into the right frontal lobe and surrounding facial structures, consistent with severe fungal disease (Image 2). Inpatient nasal endoscopy with biopsy showed fungal elements consistent with Aspergillus species. Clinical Practice and Cases in Emergency Medicine 
DISCUSSION
Aspergillus species, Fusarium species, the Mucorales, and dematiaceous (brown-black) molds are among the most common causative agents of invasive fungal sinusitis.
1,2 The chronic course is typically greater than 12 weeks and takes an indolent form that may present with little or no systemic signs or symptoms. 3, 4 Therefore, the emergency physician must maintain a high index of suspicion for such pathology. In the case of our patient, the extensive and severe nature of her pathology was not appreciated by physical examination. Physical exam should include careful inspection of the nares and oral cavity for areas of necrosis. 5 Other physical exam findings may include tenderness to palpation of the maxillary sinuses. Neurologic examination may reveal decreased sensation in malar areas and visual changes due to optic nerve and/or orbit involvement.
In general, invasive rhinosinusitis is difficult to cure and survival rates are poor. Long-term sinonasal complications such as mycotic aneurysms, cavernous sinus thrombosis, and cerebral infarcts or hemorrhage may develop. 6 Because of the poor prognosis, early diagnosis and aggressive treatment is necessary. A high index of suspicion for invasive fungal infection should be maintained in patients complaining of sinus symptoms including facial pain and headache, especially in the setting of immunocompromised status.
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